Amino-acid PET to track tumor response in IDH‑mutant gliomas (APPEAR)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, bicentric observational effort collecting longitudinal amino‑acid PET and routine MRI data in adults with histologically confirmed IDH‑mutant astrocytoma or oligodendroglioma. Participating sites will perform PET (including FET PET) during standard postoperative care and follow-up, and imaging will be interpreted using PET RANO recommendations alongside MRI/RANO evaluations. The goal is to describe PET signal changes before, during, and after treatment to distinguish true progression from treatment‑related changes. No experimental therapies are given; the study documents imaging and clinical course under usual care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 18 years
* Histologically verified diffuse IDH-mutant glioma (astrocytoma, oligodendroglioma) of any grade as defined in the WHO classification of tumors of the central nervous system
* Postoperative treatment according to current standard of care at the time of study inclusion
* Performance of amino acid PET as part of clinical routine

Exclusion Criteria:

* Inclusion in another clinical trial/investigational study involving an experimental therapy or study medication
* Inclusion criteria not met

Where it's running

• Medical University of Vienna
  Vienna, Austria Recruiting
• LMU Hospital
  Munich, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Nathalie L Albert, Prof. Dr. med. — LMU Klinikum München
• Study coordinator: Nathalie L Albert, Prof. Dr. med
• Email: Nathalie.Albert@med-uni-muenchen.de
• Phone: +4989440074646

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safusidenib in IDH1-mutant glioma after vorasidenib progression

  This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.

  Recruiting at 2 sites Phase 2 Nuvation Bio Inc. · Los Angeles, California and 11 other locations · NCT07703436

• Safusidenib as maintenance therapy for IDH1‑mutant astrocytoma and oligodendroglioma

  This trial tests whether the oral drug safusidenib can help people with IDH1‑mutant astrocytomas or oligodendrogliomas remain progression‑free longer after surgery and standard radiation/chemotherapy.

  Recruiting at 59 sites Phase 3 Nuvation Bio Inc. · Birmingham, Alabama and 60 other locations · NCT05303519

• Midline glioma MRI AI model: preoperative molecular subtyping and prognosis

  This study tests an MRI-based AI model to predict key molecular subtypes and prognosis for patients with midline gliomas before surgery.

  Recruiting Xiangya Hospital of Central South University · Changsha, Hunan · NCT07608003

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.